Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoylpiperidin- 3-yl)-propanoic acid at P1

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 361-368

  Narasimhan, Lakshmi S ^a   Rubin, J Ronald ^a   Holland, Debra R ^a   Plummer, Janet S ^a   Rapundalo, Stephen T ^a   Edmunds, Jeremy E ^a   St Denis, Yves ^b   Siddiqui, M Arshad ^b   Humblet, Christine ^a  

^a PFIZER INC   (United States)

^b Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (1 CARBAMIMIDOYL PIPERIDIN 3 YL)PROPANOIC ACID; ARGININE DERIVATIVE; LIGAND; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG STRUCTURE; MOLECULAR INTERACTION; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALANINE; AMIDINES; ARGININE; CRYSTALLOGRAPHY, X-RAY; FACTOR XA; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TRYPSIN INHIBITORS;

EID: 0034628521     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990216f     Document Type: Article

References (38)

1. Davie, E. W.; Fujikawa, K.; Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30, 10363-70.
2. Fenton, J. W., II; Ofosu, F. A.; Moon, D. G.; Maraganore, J. M. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagulation Fibrinolysis 1991, 2, 69-75.
3. Maraganore, J. M. Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb. Haemostasis 1993, 70, 208-11.
4. Maraganore, J. M. Hirudin and hirulog: Advances in antithrombotic therapy. Perspect. Drug Discovery Des. 1994, 1, 461-78.
5. Ripka, W. C.; Vlasuk, G. P. Antithrombotics/serine proteases. Annu. Rep. Med. Chem. 1997, 32, 71-89.
6. Kaiser, B. Drugs Future 1998, 23, 423-436.
7. Menear, K. Curr. Med. Chem. 1998, 5, 457-468.
8. Vacca, J. P. Annu. Rep. Med. Chem. 1998, 33, 81-90.
9. Kimball, S. D. Handb. Exp. Pharmacol. 1999, 132, 367-396.
10. De Nanteuil, G.; Verbeuren, T. J. Expert Opin. Invest. Drugs 1999, 8, 173-180.
11. Hauptmann, J.; Sturzebecher, J. Thromb. Res. 1999, 93, 203-241.
12. Sanderson, P. E. J. Med. Res. Rev. 1999, 19, 179-197.
13. Menear, K. Expert Opin. Invest. Drugs 1999, 8, 1373-1384.
14. Rydel, T. J.; Ravichandran, K. G.; Tulinsky, A.; Bode, W.; Huber, R.; Roitsch, C.; Fenton, J. W., II. The structure of a complex of recombinant hirudin and human.alpha.-thrombin. Science (Washington, D. C., 1883-) 1990, 249, 277-80.
15. Bode, W.; Turk, D.; Karshikov, A. The refined 1.9-.ANG. X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human.alpha.-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992, 1, 426-71.
16. Bode, W.; Turk, D.; Stuerzebecher, J. Geometry of binding of the benzamidine- and arginine-based inhibitors N.alpha.-(2-naphthyl-sulfonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine (NAPAP) and (2R, 4R)-4-methyl-1-[N.alpha.-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L- arginyl]-2-piperidine carboxylic acid (MQPA) to human.alpha.-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur. J. Biochem. 1990, 193, 175-82.
17. Turk, D.; Stuerzebecher, J.; Bode, W. Geometry of binding of the N.alpha.-tosylated piperidides of m-amidino-, p-amidino-and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes. FEBS Lett. 1991, 287, 133-8.
18. St. Laurent, D. R.; Balasubramanian, N.; Han, W. T.; Trehan, A.; Federici, M. E.; Meanwell, N. A.; Wright, J. J.; Seiler, S. M. Active site-directed thrombin inhibitors. II. Studies related to arginine/guanidine bioisosteres. Bioorg. Med. Chem. 1995, 3, 1145-56.
19. Hilpert, K.; Ackermann, J.; Banner, D. W.; Gast, A.; Gubernator, K.; Hadvary, P.; Labler, L.; Mueller, K.; Schmid, G.; Tschopp, T. B.; Waterbeemd, H. v. d. Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors. J. Med. Chem. 1994, 37, 3889-901.
20. Levy, O. E.; Semple, J. E.; Lim, M. L.; Reiner, J.; Rote, W. E.; Dempsey, E.; Richard, B. M.; Zhang, E.; Tulinsky, A.; Ripka, W. C.; Nutt, R. F. Potent and Selective Thrombin Inhibitors Incorporating the Constrained Arginine Mimic L-3-Piperidyl-(N-guanidino)alanine at P1. J. Med. Chem. 1996, 39, 4527-4530.
21. Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, Y. G.; Richard, B. M.; Nolan, T. G.; Hakanson Kjell; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamide Moieties. J. Med. Chem. 1996, 39, 4531-4536.
22. Krishnan, R.; Zhang, E.; Hakansson, K.; Arni, R. K.; Tulinsky, A.; Lim-Wilby, M. S. L.; Levy, O. E.; Semple, J. E.; Brunck, T. K. Highly Selective Mechanism-Based Thrombin Inhibitors: Structures of Thrombin and Trypsin Inhibited with Rigid Peptidyl Aldehydes. Biochemistry 1998, 37, 12094-12103.
23. St-Denis, Y.; Augelli-Szafran, C. E.; Bachand, B.; Berryman, K. A.; DiMaio, J.; Doherty, A. M.; Edmunds, J. E.; Leblond, L.; Levesque, S.; Narasimhan, L. S.; Penvose-Yi, J. R.; Rubin, J. R.; Tarazi, M.; Winocour, P. D.; Siddiqui, M. A. Potent Bicyclic Lactam Inhibitors of Thrombin: Part I: P3 Modifications. Bioorg. Med. Chem. 1998, 8, 3193-3198.
24. Plummer, J. S.; Berryman, K. A.; Cai, C.; Cody, W., L.; DiMaio, J.; Doherty, A., M.; Eaton, S.; Edmunds, J. J.; He, J. X.; Holland, D. R.; Lafleur, D.; Levesque, S.; Narasimhan, L. S.; Rubin, J. R.; Rapundalo, S. T.; Siddiqui, M. A.; Susser, A.; St-Denis, Y.; Winocour, P. Potent and Selective Bicyclic Lactam Inhibitors of Thrombin: Part 2: P1 Modifications. Bioorg. Med. Chem. 1998, 8, 3409-3414.
25. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-62.
26. Nakayama, Y.; Senokuchi, K.; Nakai, H.; Obata, T.; Kawamura, M. Therapeutic potential of trypsin-like serine protease inhibitors. Drugs Future 1997, 22, 285-293.
27. Schulz, G. E.; Schirmer, R. H. Principles of Protein Structure; Springer-Verlag: New York, 1979.
28. Richards, F. M. Calculation of molecular volumes and areas for structures of known geometry. Methods Enzymol. 1985, 775, 440-64.
29. Connolly, M. L. The molecular surface package. J. Mol. Graphics 1993, 11, 139-41.
30. Note: Crystallographically obtained conformations of small molecules present as receptor complexes tend to have small variations in bond lengths, bond angles, and torsions from canonical values used by molecular mechanics force fields. This could translate to large strain energies when evaluated using molecular mechanics. Proper treatment of strain energies across four enzyme complexes where the inhibitors are covalently attached to the enzyme is beyond the scope of this work. Hence a comparison of strain energies for the bound conformations of the inhibitors is not considered.
31. Le Bonniec, B. F.; Esmon, C. T. Glu-192→Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7371-5.
32. Guinto, E. R.; Ye, J.; Le Bonniec, B. F.; Esmon, C. T. Glu192→Gln substitution in thrombin yields an enzyme that is effectively inhibited by bovine pancreatic trypsin inhibitor and tissue factor pathway inhibitor. J. Biol. Chem. 1994, 269, 18395-400.
33. Neuenschwander, P. F.; Morrissey, J. H. Alteration of the Substrate and Inhibitor Specificities of Blood Coagulation Factor VIIa: Importance of Amino Acid Residue K192. Biochemistry 1995, 34, 8701-7.
34. Abola, E. E.; Sussman, J. L.; Prilusky, J.; Manning, N. O. Protein Data Bank archives of three-dimensional macromolecular structures. Methods Enzymol. 1997, 277, 556-571.
35. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park, C. H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of human Des(1-45) factor Xa at 2.2.ANG. resolution. J. Mol. Biol. 1993, 232, 947-66.
36. Bartunik, H. D.; Summers, L. J.; Bartsch, H. H. Crystal structure of bovine.beta.-trypsin at 1.5.ANG. resolution in a crystal form with low molecular packing density. Active site geometry, ion pairs and solvent structure. J. Mol. Biol. 1989, 210, 813-28.
37. Skrzypczak-Jankun, E.; Carperos, V. E.; Ravichandran, K. G.; Tulinsky, A.; Westbrook, M.; Maraganore, J. M. Structure of the hirugen and hirulog 1 complexes of.alpha.-thrombin. J. Mol. Biol. 1991, 221, 1379-93.
38. Brunger, A. T. X-PLOR Version 3.1 manual; Yale University Press: New Haven, CT, 1992.